<DOC>
	<DOCNO>NCT01157403</DOCNO>
	<brief_summary>Type 1 diabetes mellitus ( T1DM ) characterize autoimmune destruction pancreatic β cell ; result , patient T1DM dependent exogenous insulin control blood glucose continuously . Bone marrow-derived mesenchymal stem cell show many animal study potential cure T1DM , could address need β-cell replacement also control autoimmune response cell express insulin . Therefore need study safety efficacy autologous bone marrow mesenchymal stem cell treatment newly diagnose patient T1DM .</brief_summary>
	<brief_title>Autologous Transplantation Mesenchymal Stem Cells Treatment Patients With Onset Type 1 Diabetes</brief_title>
	<detailed_description>Autologous transplantation Bone marrow mesenchymal stem cell ( approximately 2.5 x 106 cells/kg body weight ) intravenously</detailed_description>
	<criteria>1 . Ability provide write informed consent patient Child guardian 2 . Confirmed diagnosis type 1 diabetes ADA criterion less 18 week • 1 . Body Mass Index &gt; 30 2 . Presence acute stage Active infection , recent myocardial infarction , recent cerebral vascular accident ( CVA ) acute renal failure . 3 . Severe Organ damage ( e.g . lung disease , hematopoietic dysfunction , liver dysfunction ) . 4 . Infectious disease , e.g . HIV infection , hepatitis B C infection 5 . Presence malignancy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>mesenchymal stem cell</keyword>
</DOC>